00:17 , Aug 3, 2010 |  BC Extra  |  Company News

Astellas submits mirabegron NDA in Japan

Astellas Pharma Inc. (Tokyo:4503) disclosed in its quarterly financial results that it submitted an NDA in Japan for mirabegron ( YM178) to treat urinary frequency, urinary incontinence or urgency associated with overactive bladder. The adrenergic...